Stock EBS EMERGENT BIOSOLUTIONS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Emergent BioSolutions Inc.

Equities

EBS

US29089Q1058

Pharmaceuticals

Market Closed - Nyse
Other stock markets
 04:00:02 2024-04-24 pm EDT 		5-day change 1st Jan Change
2.18 USD -4.80% Intraday chart for Emergent BioSolutions Inc. +14.74% -9.17%
Apr. 24 Amneal Pharmaceuticals Cleared by FDA to Sell Generic Version of Nasal Spray to Treat Opioid Overdose -- Shares Rise MT
Mar. 25 Emergent Gets FDA's 'No Action Indicated' Status For Baltimore Bayview Manufacturing Facility MT

Business Summary

Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a Bioservices portfolio. Its segments include Commercial Products, MCM Products, and Services Segment. Commercial Products segment include NARCAN (naloxone HCl). MCM Products segment consists of its Anthrax - MCM, Smallpox - MCM and Other Products. Services segment consisting of its Bioservices offerings. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression. Its portfolio of Bioservices consists of three but interrelated service pillars, such as development services (process and analytical development) and drug substance manufacturing.

Number of employees: 1,600

Sales per Business

USD in Million2022Weight2023Weight Delta
Commercial Products
47.4 %
- - 497 47.4 % -
Medical Countermeasures Products
42.6 %
- - 447 42.6 % -
Services
7.5 %
- - 79 7.5 % -
Reconciling Items
2.5 %
41 3.7 % 26 2.5 % -36.47%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
57.9 %
890 79.4 % 607 57.9 % -31.74%
Canada
21.4 %
149 13.3 % 224 21.4 % +50.87%
Other
20.8 %
83 7.4 % 218 20.8 % +163.16%

Managers

Managers TitleAgeSince
Joseph Papa CEO
 Chief Executive Officer 68 Feb. 20
Richard Lindahl DFI
 Director of Finance/CFO 70 18-03-25
Kelly Warfield CTO
 Chief Tech/Sci/R&D Officer - 23-03-16
Coleen Glessner CMP
 Compliance Officer 53 20-02-29
Laura Kennedy CMP
 Compliance Officer - 16-08-31
Sharon Solomon CTO
 Chief Tech/Sci/R&D Officer - 17-02-28
Michelle Pepin HRO
 Human Resources Officer - 23-03-16
Stephanie Duatschek PRN
 Corporate Officer/Principal - -
Aubrey Watkins PRN
 Corporate Officer/Principal - -
Christopher W. Frech LAW
 General Counsel - 09-01-31

Members of the board

Members of the board TitleAgeSince
Keith Katkin BRD
 Director/Board Member 52 22-03-31
Marvin White BRD
 Director/Board Member 62 10-05-31
Louis Sullivan BRD
 Director/Board Member 90 04-12-31
Ronald Richard BRD
 Director/Board Member 68 04-12-31
Zsolt Pál Harsányi CHM
 Chairman 80 04-07-31
Neal Fowler BRD
 Director/Board Member 62 23-09-27
Sujata Dayal BRD
 Director/Board Member 61 22-07-14
Donald DeGolyer BRD
 Director/Board Member 63 23-09-27
Kathryn Zoon BRD
 Director/Board Member 75 16-09-30

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 57,990,764 51,406,736 ( 88.65 %) 5,600,000 ( 9.657 %) 88.65 %

Shareholders

NameEquities%Valuation
BlackRock Advisors LLC
16.10 %
8,406,523 16.10 % 21 M $
Vanguard Fiduciary Trust Co.
5.698 %
2,974,638 5.698 % 8 M $
Charles Schwab Investment Management, Inc.
5.505 %
2,873,984 5.505 % 7 M $
Millennium Management LLC
4.014 %
2,095,662 4.014 % 5 M $
Hotchkis & Wiley Capital Management LLC
3.155 %
1,647,243 3.155 % 4 M $
Morgan Stanley Investment Management, Inc.
2.366 %
1,235,356 2.366 % 3 M $
D.E. Shaw & Co., Inc.
2.273 %
1,186,552 2.273 % 3 M $
Geode Capital Management LLC
2.102 %
1,097,219 2.102 % 3 M $
Two Sigma Advisers LP
2.084 %
1,087,700 2.084 % 3 M $
STATE STREET CORPORATION
2.036 %
1,062,951 2.036 % 3 M $

Company contact information

Emergent BioSolutions, Inc.

300 Professional Drive Suite 400

20879, Gaithersburg

+240 631 3200

http://www.emergentbiosolutions.com
address Emergent BioSolutions Inc.(EBS)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per Business

Sales per region

Ratings for Emergent BioSolutions Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
2.18 USD
Average target price
5 USD
Spread / Average Target
+129.36%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
EMERGENT BIOSOLUTIONS INC. Stock Emergent BioSolutions Inc.
-9.17% 120M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.61% 672B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+25.87% 570B
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.24% 360B
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.49% 321B
ABBVIE INC. Stock AbbVie Inc.
+8.28% 300B
ASTRAZENECA PLC Stock AstraZeneca PLC
+7.09% 217B
ROCHE HOLDING AG Stock Roche Holding AG
-9.12% 204B
NOVARTIS AG Stock Novartis AG
+5.01% 199B
PFIZER, INC. Stock Pfizer, Inc.
-8.75% 149B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. EBS Stock
  4. Company Emergent BioSolutions Inc.